Sponsored by
A longer-term analysis of the Phase 3 INDIGO trial was just published in The Lancet Oncology, and it confirms the durable benefit of Voranigo (vorasidenib)—the first targeted therapy FDA approved for Grade 2 IDH-mutant glioma in 2024. With an additional six months of trial follow-up, patients on Voranigo continued to show prolonged progression-free survival and delayed need for further intervention compared to placebo, along with sustained reductions in tumor growth and seizure frequency and no new safety issues. These data strengthen confidence that Voranigo offers meaningful and durable disease control for patients with low-grade IDH-mutant glioma. Use of the drug in Grade 3 or 4 IDH-mutant brain tumros remains investigational, but there are some ongoing studies that will hopefully yield evidence on the impact in higher grade cancers in the near future.